文献速递前列腺癌

转移性激素敏感性前列腺癌患者随机接受雄激素剥夺治疗+恩扎卢胺±唑来膦酸后全身及区域体成分变化:BONENZA研究

Total and Regional Changes in Body Composition in Metastatic Hormone-sensitive Prostate Cancer Patients Randomized to Receive Androgen Deprivation + Enzalutamide ± Zoledronic Acid. The BONENZA Study.
PubMed 文献 · Eur Urol Oncol · 2025-04-28

BONENZA是一项前瞻性2期试验,转移性激素敏感性前列腺癌患者随机接受ADT+恩扎卢胺联合(EZ组)或不联合(E组)唑来膦酸。89例患者基线和治疗18个月后均有配对DXA评估,结果显示FBM增加+22.8%、LBM减少-6.7%、ALMI降低-9.2%,区域变化差异大,无患者符合肌少性肥胖标准。

要点

  • ADT联合ARPI治疗18个月后,FBM增加+22.8%、LBM减少-6.7%、ALMI降低-9.2%(均p<0.001)。
  • FBM增加区域差异大,从右臂+36.1%(p<0.001)至头部+3.7%(p<0.01)。
  • 年龄<70岁和基线LBM较高的患者体成分变化更显著。

核心结论

  • ADT联合ARPI治疗后体成分发生显著变化,FBM增加和LBM减少幅度约为单用ADT预期变化的两倍。
  • DXA被证明是监测体成分的可靠工具,评估区域变化有助于实施个体化监督体育锻炼以预防肌少性肥胖风险。

研究设计与样本

  • BONENZA(NCT03336983)是一项前瞻性2期试验,转移性激素敏感性前列腺癌患者随机接受ADT+恩扎卢胺联合(EZ组)或不联合(E组)唑来膦酸。
  • 89例患者(EZ组46例,E组43例)在基线和治疗18个月后均有配对DXA评估。

主要发现

  • 治疗18个月后,FBM增加+22.8%(p<0.001),LBM减少-6.7%(p<0.001),ALMI降低-9.2%(p<0.001)。
  • FBM增加区域差异大,从右臂+36.1%(p<0.001)至头部+3.7%(p<0.01)。
  • LBM减少范围从右臂-9.4%(p<0.001)至躯干-6.4%(p<0.001)。
  • 无患者符合肌少性肥胖标准;治疗18个月后,11.76%患者FBM>40.8%,3.5%患者ALMI<5.5,ALMI/FBM比值降低-23.9%(p<0.001)。
  • 年龄和基线LBM显著影响体成分变化,年轻患者(<70岁)和基线LBM较高者变化更明显。

临床怎么用

  • 作者认为DXA是监测体成分的可靠工具,评估区域变化有助于实施个体化监督体育锻炼以预防肌少性肥胖风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: The reduction of lean body mass (LBM) and the increase of fat body mass (FBM) caused by androgen deprivation therapy (ADT) administered to prostate cancer patients are well known to lead to an increased risk of sarcopenia. The effects of the addition of androgen receptor pathway inhibitors (ARPIs) to ADT on body composition have not been studied thoroughly. METHODS: BONENZA (NCT03336983) is a prospective phase 2 trial in which metastatic hormone-sensitive prostate cancer patients were randomized to receive ADT plus enzalutamide with (EZ arm) or without (E arm) the addition of zoledronic acid. Total and regional body composition parameters were evaluated by dual-energy x-ray absorptiometry (DXA) scans at baseline and after 18 mo of therapy. KEY FINDINGS AND LIMITATIONS: Eighty-nine patients (46 from the EZ arm and 43 from the E arm) had paired DXA evaluation at both time points. After 18 mo of therapy, FBM increased by +22.8% (p < 0.001), LBM reduced by -6.7% (p < 0.001), and appendicular lean mass index (ALMI) decreased by -9.2% (p < 0.001). The increase in FBM varied considerably according to body districts: from +36.1% in the right arms (p < 0.001) to +3.7% in the head (p < 0.01). Similarly, the decrease in LBM ranged from -9.4% (p < 0.001) in the right arm to -6.4% (p < 0.001) in the trunk. None of the patients met the criteria for sarcopenic obesity; however, after 18 mo of treatment, 11.76% of patients had FBM >40.8%, 3.5% of patients had an ALMI of <5.5, and the ALMI/FBM ratio decreased by -23.9% (p < 0.001). Age and baseline LBM influenced these body composition changes significantly, with younger patients (<70 yr) and those with higher baseline LBM experiencing more marked changes. CONCLUSIONS AND CLINICAL IMPLICATIONS: Body composition undergoes a significant change with the addition of ARPIs to ADT, with an increase in FBM and a reduction in LBM, which are twice as high as those expected with ADT alone. DXA has been proved to be a reliable tool for monitoring body composition, and an assessment of district variations can aid in implementing individual-supervised physical exercise to prevent the risk of sarcopenic obesity.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Buffoni M, Dalla Volta A, Valcamonico F, et al. Total and Regional Changes in Body Composition in Metastatic Hormone-sensitive Prostate Cancer Patients Randomized to Receive Androgen Deprivation + Enzalutamide ± Zoledronic Acid. The BONENZA Study. Eur Urol Oncol. 2025. PMID: 40300921. doi:10.1016/j.euo.2025.02.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。